The 30 references in paper P. Rumyantsev O., П. Румянцев О. (2015) “РЕФРАКТЕРНОСТЬ ВЫСОКОДИФФЕРЕНЦИРОВАННОГО РАКА ЩИТОВИДНОЙ ЖЕЛЕЗЫ К ЛЕЧЕНИЮ РАДИОАКТИВНЫМ ЙОДОМ // REFRACTORY OF WELL-DIFFERENTIATED THYROID CANCER TO THE TREATMENT WITH RADIOACTIVE IODINE” / spz:neicon:ogsh:y:2013:i:3:p:11-15

1
Румянцев П.О., Ильин А.А., Румянцева У.В., Саенко В.А. Рак щитовидной железы. Современные подходы к диагностике и лечению. М.: ГЭОТАР-Медиа, 2009.
(check this in PDF content)
2
Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;8:2892–9.
(check this in PDF content)
3
Schlumberger M., Lacroix L., Russo D. et al. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab 2007;3:260–9.
(check this in PDF content)
4
Schlumberger M.J. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;5:297–306.
(check this in PDF content)
5
Hodak S.P., Carty S.E. Radioiodineresistant differentiated thyroid cancer: hope for the future. Oncology 2009;9:775–6.
(check this in PDF content)
6
Capdevila J., Argiles G., RodriguezFrexinos V. et al. New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era. Discov Med 2010;45:153–62.
(check this in PDF content)
7
Sabra M.M., Dominguez J.M., Grewal R.K. et al. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab 2013;5:E829–36.
(check this in PDF content)
8
Cooper D.S., Doherty G.M., Haugen B.R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;11:1167–214.
(check this in PDF content)
9
Haugen B.R. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 1999;1:34–41.
(check this in PDF content)
10
Argiris A., Agarwala S.S., Karamouzis M.V. et al. A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs 2008;2:183–8.
(check this in PDF content)
11
Shimaoka K., Schoenfeld D.A., DeWys W.D. et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;9:2155–60.
(check this in PDF content)
12
Altucci L., Leibowitz M.D., Ogilvie K.M. et al. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007;10:793–810.
(check this in PDF content)
13
Gruning T., Tiepolt C., Zophel K. et al. Retinoic acid for redifferentiation of thyroid Результаты клинических исследований II фазы различных мультикиназных ингибиторов у больных ВДРЩЖ, резистентным к лечению радиоактивным йодом ПрепаратМолекулярные мишениГистологический тип РЩЖЧисло пациентовОтветПобочные эффектыСсылка Сунитиниб VEGFR-2; PDGRF; FLT3; KIT ВДРЩЖ 80 % МРЩЖ 20 %35 ПР – 3 % ЧР – 28 % СО – 46 % Нейтропения (34 %) Лейкопения (31 %) ЛПС (17 %) Диарея (17 %) Слабость (11 %) [24] ВДРЩЖ 86 % МРЩЖ 14 %43 ЧР – 13 % СО – 68 % Слабость (79 %) Диарея (56 %) ЛПС (53 %) Нейтропения (49 %) Гипертензия (42 %) [25] ВДРЩЖ 60 % МРЩЖ 34 % АРЩЖ 6 % 17ЧР – 6 % СО – 71 % Гипертензия (41 %) Мукозит (30 %) ЛПС (12 %) [26] Вандетаниб (AZ6474) RAF; RET; VEGFR-1,-2,-3; EGFR ВДРЩЖ и плацебо 1
(check this in PDF content)
14
Short S.C., Suovuori A., Cook G. et al. A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin Oncol (R Coll Radiol) 2004;8:569–74.
(check this in PDF content)
15
O'Neill C.J., Oucharek J., Learoyd D., Sidhu S.B. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 2010;2:146–56.
(check this in PDF content)
16
Fagin J.A., Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 2008;6:955–69.
(check this in PDF content)
17
Klein M., Picard E., Vignaud J. M. et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 1999; 1:41–9.
(check this in PDF content)
18
Chougnet C., Brassard M., Leboulleux S. et al. Molecular targeted therapies for patients with refractory thyroid cancer. Clin Oncol (R Coll Radiol) 2010;6:448–55.
(check this in PDF content)
19
Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev
(check this in PDF content)
20
7;7:742–62. 20. Knauf J.A., Fagin J.A. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol 2009;2:296–303.
(check this in PDF content)
21
O'Neill J.P., Power D., Condron C. et al. Anaplastic thyroid cancer, tumorigenesis and therapy. Ir J Med Sci 2010;1:9–15.
(check this in PDF content)
22
Ho A. L., Grewal R. K., Leboeuf R. et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013;7:623–32.
(check this in PDF content)
23
Chen L., Shen Y., Luo Q. et al. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. Thyroid 2011;2:119–24.
(check this in PDF content)
24
Carr L.L., Mankoff D.A., Goulart B.H. et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;21:5260–8.
(check this in PDF content)
25
Perez C.A., Santos E.S., Arango B.A. et al. Novel molecular targeted therapies for refractory thyroid cancer. Head Neck 2012;5:736–45.
(check this in PDF content)
26
Kojic K.L., Kojic S.L., Wiseman S.M. Differentiated thyroid cancers: a comprehensive review of novel targeted therapies. Expert Rev Anticancer Ther 2012;3:345–57.
(check this in PDF content)
27
Leboulleux S., Bastholt L., Krause T. et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012;9: 897–905.
(check this in PDF content)
28
Gupta-Abramson V., Troxel A.B., Nellore A. et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;29:4714–9.
(check this in PDF content)
29
Hoftijzer H., Heemstra K.A., Morreau H. et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;6:923–31.
(check this in PDF content)
30
Kloos R.T., Ringel M.D., Knopp M.V. et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;10: 1675–84.
(check this in PDF content)